SCHEMBL458496

SCHEMBL458496

COc1cc(OC)c(-c2c(OC)cc(OC)cc2P(c2ccccc2)c2ccccc2)c(P(c2ccccc2)c2ccccc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTR6 P50406 1/20 0.40
CYP3A4 P08684 4/20 0.40
CYP1A2 P05177 4/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.39
ABCG2 Q9UNQ0 2/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CA4 P22748 2/20 0.39
CYP1A1 P04798 3/20 0.39
CYP1B1 Q16678 3/20 0.39
CYP2E1 P05181 1/20 0.39
CYP2C8 P10632 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2A6 P11509 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10073379 0.92 LMNA (0.36) LMNAMAPTSMN1; SMN2HTR6CYP3A4
SCHEMBL28423522 0.88 CYP1A1 (0.50) MAPTSMN1; SMN2CYP3A4CYP1A2ALDH1A1
SCHEMBL10073368 0.88 CA12 (0.44) LMNAMAPTCYP3A4CYP1A2ALDH1A1
SCHEMBL458029 0.85 ACHE (0.41) LMNAMAPTSMN1; SMN2CYP3A4CYP1A2
SCHEMBL16005619 0.83 CNR2 (0.41) LMNACYP3A4ALDH1A1CA4CYP2D6
SCHEMBL4976814 0.81 LMNA (0.43) LMNAMAPTSMN1; SMN2HTR6CYP3A4
SCHEMBL30018007 0.81 ALDH1A1 (0.41) LMNAMAPTSMN1; SMN2CYP3A4CYP1A2
SCHEMBL28521698 0.81 CA12 (0.48) LMNAMAPTSMN1; SMN2CYP3A4CYP1A2
SCHEMBL458412 0.81 ALDH1A1 (0.41) LMNAMAPTSMN1; SMN2CYP3A4CYP1A2
SCHEMBL30017862 0.81 ALDH1A1 (0.41) LMNAMAPTSMN1; SMN2CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710422-B1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES SYNGENTA CROP PROTECTION AG (CH) 2026-01-07 EP claimed
US-11053188-B2 Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides SYNGENTA PARTICIPATIONS AG (CH) 2021-07-06 US claimed
US-20200407311-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES SYNGENTA PARTICIPATIONS AG (CH) 2020-12-31 US claimed
EP-3710422-B1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES SYNGENTA CROP PROTECTION AG (CH) 2026-01-07 EP disclosed
WO-2025056767-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ALIPHATIC AMINES SYNGENTA CROP PROTECTION AG (CH) 2025-03-20 WO disclosed
WO-2021212974-A1 RACEMIC AND CHIRAL 3-(2,3-BUTADIENYL)OXYINDOLINONE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 复旦大学 (CN) 2021-10-28 WO disclosed
US-11053188-B2 Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides SYNGENTA PARTICIPATIONS AG (CH) 2021-07-06 US disclosed
US-20200407311-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES SYNGENTA PARTICIPATIONS AG (CH) 2020-12-31 US disclosed
WO-2016029216-A2 METHOD FOR PRODUCING AMIDINE DERIVATIVES BIOCRYST PHARMACEUTICALS, INC. (US) 2016-02-25 WO disclosed
US-9062085-B2 Biaryl diphosphine ligands, intermediates of the same and their use in asymmetric catalysis KANATA CHEMICAL TECHNOLOGIES INC. (CA) 2015-06-23 US disclosed
US-9062085-B2 Biaryl diphosphine ligands, intermediates of the same and their use in asymmetric catalysis KANATA CHEMICAL TECHNOLOGIES INC. (CA) 2015-06-23 US disclosed
US-20130184479-A1 BIARYL DIPHOSPHINE LIGANDS, INTERMEDIATES OF THE SAME AND THEIR USE IN ASYMMETRIC CATALYSIS KANATA CHEMICAL TECHNOLOGIES INC. (CA) 2013-07-18 US disclosed
US-20130184479-A1 BIARYL DIPHOSPHINE LIGANDS, INTERMEDIATES OF THE SAME AND THEIR USE IN ASYMMETRIC CATALYSIS KANATA CHEMICAL TECHNOLOGIES INC. (CA) 2013-07-18 US disclosed
WO-2012031358-A1 BIARYL DIPHOSPHINE LIGANDS, INTERMEDIATES OF THE SAME AND THEIR USE IN ASYMMETRIC CATALYSIS KANATA CHEMICAL TECHNOLOGIES INC. (CA) 2012-03-15 WO disclosed
EP-0829463-B2 Process for preparing an (E)-(R)-2-alkyl-4-(2,2,3-trimethylcyclopent-3-en-1-yl)-2-buten-1-ol TAKASAGO PERFUMERY CO LTD (JP) 2008-11-05 EP disclosed
EP-0829463-B1 (E)-(R)-2-Alkyl-4-(2,2,3-trimethylcyclopent-3-en-1-yl)-2-buten-1-ol, process for preparing the same, and use thereof in perfume compositions TAKASAGO PERFUMERY CO LTD (JP) 2001-12-19 EP disclosed
US-6084138-A CATALYST SELECTIVE AND STEREOSPECIFIC REDUCTION OF CORRESPONDING ALDEHYDE IN THE PRESENCE OF A RUTHENIUM-PHOSPHINE COMPLEX CATALYST, AN ALKALI OR ALKALINE EARTH METAL BASE AND AN AMINE TAKASAGO INTERNATIONAL CORPORATION (JP) 2000-07-04 US disclosed
US-5994291-A (E)-(R)-2-alkyl-4-(2,2,3,-Trimethylcyclopent-3-en-1-yl)-2-buten-1-ol, process for preparing the same, and use thereof TAKASAGO INTERNATIONAL COPORATION (JP) 1999-11-30 US disclosed
US-5856590-A HYDROGENATING 4-T-BUTYLCYCLOHEXANONE BY USING A SPECIFIC RUTHENIUM-PHOSPHINE COMPLEX AS A CATALYST IN THE PRESENCE OF A BASE TAKASAGO INTERNATIONAL CORPORATION (JP) 1999-01-05 US disclosed
US-5750804-A HYDROGENATING 3-ISOCAMPHYLCYCLOHEXANONE USING RUTHENIUM/PHOSPHINE COMPLEX CATALYST IN PRESENCE OF ALKALI METAL OR ALKALINE EARTH METAL AND AMINE BASE TAKASAGO INTERNATIONAL CORPORATION (JP) 1998-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407311-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES TBCB, ADORA2B, ADRA2B LMNA 1349/4885MAPT 3180/4885SMN1; SMN2 2748/4885
US-20130184479-A1 BIARYL DIPHOSPHINE LIGANDS, INTERMEDIATES OF THE SAME AND THEIR USE IN ASYMMETRIC CATALYSIS AGPS, COASY, BLVRB LMNA 4638/4885MAPT 4543/4885SMN1; SMN2 4817/4885
US-11053188-B2 Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides TBCB, ADORA2B, CCNB3 LMNA 1332/4885MAPT 2835/4885SMN1; SMN2 2693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.